- LXRP’s patented DehydraTECH technology will be employed by each wholly owned subsidiary, with applications applied to the industry segments
- At its 2018 Annual General and Special Meeting (AGM), all motions were passed, including election of board members and approval of its conversion plan
- Move to convert the company from a U.S.-based firm to Canada-based is placed on ‘indefinite hold’ due to inequitable tax treatment issue; LXRP to seek a resolution
At Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) 2018 Annual General Meeting, all motions were passed. The company is proceeding on schedule with its reorganization into four new wholly owned subsidiaries to serve the nicotine, hemp, pharmaceutical and cannabis industries. All of these subsidiaries will utilize the company’s patented DehydraTECH® proprietary absorption technology for application to their own sectors (http://cnw.fm/9f8pK). The company said that the reorganization will assist in the growth and evolution of each of the four subsidiaries, including, but not limited to, the areas of research, development and finance.
Also during the annual meeting, Chris Bunka, John Docherty, Nick Baxter and Ted McKechnie won election as directors. In addition, the appointment of auditors was approved, as was the plan of conversion.
LXRP is a biotechnology company that out-licenses its disruptive delivery technology that promotes healthier ingestion methods. It results in lower dosing and higher effectiveness. LXRP holds a patent for oral delivery of all cannabinoids. It has a growing IP portfolio and will license in any of the 40 countries worldwide where its technology already has a patent or is patent-pending.
It was also decided that the planned change of domicile of LXRP from a U.S.-based company to a Canadian-based firm will be placed on ‘indefinite hold’ due to the issue of inequitable tax treatment of a certain class of stockholders. LXRP reported that tax experts informed the company that the move may create punitive taxes for some shareholders.
If a resolution to the tax issue is found, the plan of conversion could take place in the future. If inequitable tax treatment cannot be resolved, the conversion will not occur, LXRP noted.
For more information, visit the company’s website at www.LexariaBioscience.com
More from CannabisNewsWire
About CBDWire
CBDWire (CBDW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CBDNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CBDW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled visibility, recognition and brand awareness. CBDW is where news, content and information converge.
For more information please visit https://www.cbdwire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
CBDWire (CBDW)
Denver, Colorado
cbdwire.com
303.498.7722 Office
Editor@CBDWire.com
